Lymphoma Clinical Trials in Denver

Showing 221-240 of 266 trials

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

NCT00051701

The purpose of this study is to determine the optimal dose of Campath for patients with relapsing or refractory (failed standard therapy) non-Hodgkin's lymphoma. The study will also evaluate the safety of the drug and whether it is effective in treating these patients.

Non-Hodgkins Lymphoma

Genzyme, a Sanofi Company61 participantsStarted Dec 2002

Aurora, Colorado, United States • Colorado Springs, Colorado, United States • Denver, Colorado, United States +14 more locations

TERMINATEDPHASE28.4 miles

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory

Astellas Pharma Inc41 participantsStarted Jun 2007

Beverly Hills, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Lymphoma Trials in Other Cities

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Imexon for Relapsed Follicular and Aggressive Lymphomas

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Other Conditions in Denver